If so, you should be aware of the opportunity to participate in the ROADS Clinical Study.
This important clinical study compares 2 FDA-cleared radiation treatments that are proven safe and effective: GammaTile® Surgically Targeted Radiation Therapy (STaRT) and stereotactic radiotherapy (SRT).
The ROADS Clinical Study is enrolling now at participating hospitals across the country.
For more information contact a participating hospitals or take the ROADS Patient Evaluation.
Metastatic brain tumors (also called secondary brain tumors) are caused by cancer cells that have metastasized or spread to the brain from a different part of the body.
Radiation therapy kills cancer cells and shrinks tumors. It is often combined with surgery and chemotherapy to help eliminate any remaining tumor cells and prevent the tumor from returning.1-3
The ROADS Clinical Study will provide more information about how effective GammaTile and SRT are at preventing brain tumor recurrence.
Study participants will be randomly divided into 2 treatment groups:
Following brain tumor removal surgery, clinical study participants will receive either GammaTile or SRT to the area where the tumor was.
Study participants in both groups may have additional brain tumors that may not be suitable for surgical removal. These remaining brain tumors will be treated with SRT.
References:
The ROADS Study is sponsored by GT Medical Technologies, Inc., the makers of GammaTile. Please discuss the risks and benefits of participating in this clinical study with your care team.
Indications
GammaTile is indicated to deliver radiation therapy in patients with newly diagnosed malignant and recurrent brain tumors. Possible complications can occur with any neurosurgical procedure and include cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation. For full product and safety information, speak to your physician and refer to the instructions for use.